Revenue
No reported data
Context Therapeutics Inc. (CNTX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $31.9M | $22.7M | $17.8M | $7.1M | $3.8M | $1.6M |
| Operating income | −$39.7M | −$29.9M | −$25.1M | −$15.4M | −$10.5M | −$2.6M |
| EBITDAderived | −$39.7M | −$29.9M | −$25.1M | −$15.4M | −$10.5M | — |
| Net income | −$36.1M | −$26.7M | −$24.0M | −$14.8M | −$10.5M | $6.6M |
| Basic EPSper diluted share | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | $3.07 |
| Diluted EPSper diluted share | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | -$3.96 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 9, 2025Form 4 | Lehr Martin A.Chief Executive Officer | BuyCommon Stock · indirect | 100.0K | $0.70 | $70.0K | 920.2K |
| Jun 6, 2025Form 4 | Levit Alex C.Chief Legal Officer, Corp. Sec | BuyCommon Stock | 20.0K | $0.58 | $11.6K | 29.0K |
| Jun 6, 2025Form 4 | Minai-Azary Jennifer LynnChief Financial Officer | BuyCommon Stock | 40.0K | $0.64 | $25.6K | 80.0K |